Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfenex names FDA's John Taylor to board

This article was originally published in Scrip

Executive Summary

Pfenex, a clinical-stage biotechnology company developing biosimilar therapeutics and difficult to manufacture proteins, has appointed John Taylor to its board of directors. Mr Taylor joins Pfenex's board after a distinguished career with the US FDA, most recently in the position of counselor to the commissioner, and previously acting deputy principal commissioner and deputy commissioner for global regulatory operations and policy. Currently Mr Taylor is a principal at Greenleaf Health, a full-service consulting firm that provides strategic guidance to FDA-regulated companies that are developing innovative solutions to pressing public health challenges.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts